Fig. 3From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanyAdditive study design with added benefit and BSC as ACT. Multiplicative and additive premiums are presented for cases with an additive study design with added benefit and best supportive care as appropriate comparative therapyBack to article page